Bingyu Mao

Bingyu Mao

Auto-generated profile, based on publicly available information

Bingyu Mao

McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, 7000 Fannin, Suite 600, Houston, TX, United States, 1 713-500-3629, 1 713-500-3929

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
MNMasayuki Nigo
Masayuki Nigo
LRLaila Rasmy
Laila Rasmy
BMBingyu Mao
Bingyu Mao
BKBijun Sai Kannadath
Bijun Sai Kannadath
ZXZiqian Xie
Ziqian Xie
DZDegui Zhi
Degui Zhi
Methicillin-resistant Staphylococcus aureus (MRSA) poses significant morbidity and mortality in hospitals. Rapid, accurate risk stratification of MRSA is crucial for optimizing antibiotic therapy. Our study introduced a deep learning model, PyTorch_EHR, which leverages electronic health record (EHR) time-series data, including wide-variety patient specific data, to predict MRSA culture positivity within two weeks. 8,164 MRSA and 22,393 non-MRSA patient events from Memorial Hermann Hospital System, Houston, Texas are used for model development. PyTorch_EHR outperforms logistic regression (LR) and light gradient boost machine (LGBM) models in accuracy (AUROCPyTorch_EHR = 0.911, AUROCLR = 0.857, AUROCLGBM = 0.892). External validation with 393,713 patient events from the Medical Information Mart for Intensive Care (MIMIC)-IV dataset in Boston confirms its superior accuracy (AUROCPyTorch_EHR = 0.859, AUROCLR = 0.816, AUROCLGBM = 0.838). Our model effectively stratifies patients into high-, medium-, and low-risk categories, potentially optimizing antimicrobial therapy and reducing unnecessary MRSA-specific antimicrobials. This highlights the advantage of deep learning models in predicting MRSA positive cultures, surpassing traditional machine learning models and supporting clinicians’ judgments.

1 May 2026 in medRxiv
Verified
Preprint
Open access
PDF file
BMBingyu Mao
Bingyu Mao
MPMade K. Prasadha
Made K. Prasadha
ZXZiqian Xie
Ziqian Xie
JHJianping He
Jianping He
MGMichael Ghebranious
Michael Ghebranious
LRLaila Rasmy
Laila Rasmy
Background: Electronic health records (EHRs) with clinical decision support tools are now ubiquitous in healthcare organizations. Clinical foundation models (CFMs) pretrained on large-scale, heterogeneous structured EHR data have emerged as a powerful approach to improve predictive performance and generalizability. Meanwhile, large language models (LLMs) pretrained on broad data sources are being applied to an expanding range of healthcare tasks. However, it remains unclear whether generalist LLMs can match specialized CFMs for disease risk prediction using structured clinical data. Methods: We compared CFMs (Med-BERT, CLMBR) against fine-tuned generalist LLMs (Mistral, LLaMA-2/3/3.1), a clinical LLM (Me-LLaMA), and LLM-generated embeddings paired with simple classifiers (using DeepSeek, Qwen3, and GPT-OSS) on two disease risk prediction tasks: heart failure risk among diabetic patients (DHF) and pancreatic cancer diagnosis (PaCa). Evaluations spanned multi-site EHR data, claims data, and an open-source single-institution benchmark (EHRSHOT). Performance was assessed using the area under the receiver operating characteristic curve (AUROC) and the area under the precision-recall curve (AUPRC). Results: On larger EHR and claims cohorts (>30,000 patients), fine-tuned CFMs outperformed fine-tuned LLMs by a small but statistically significant margin (<1% AUROC). The clinical LLM performed comparably to generalist LLMs despite being smaller. On the open-source PaCa cohort (3,810 patients, 199 cases), LLMs achieved slightly higher AUROCs that were not statistically significant (LLaMA-3.1-70B 86.1% vs. Med-BERT 85.3%, p=0.27), but CFMs achieved significantly higher AUPRC (Med-BERT 55.9% vs. LLaMA-3.1-70B 41.1%, p=0.001). Notably, LLM-generated trajectory embeddings paired with logistic regression or a simple MLP, without any LLM fine-tuning, achieved the best overall performance, with AUROC exceeding 90% (Qwen3) and AUPRC reaching 66% (GPT-OSS 20B). Conclusion: LLM-generated embeddings with lightweight classifiers outperformed both fine-tuned CFMs and fine-tuned LLMs on AUROC and AUPRC. While these results demonstrate the potential of generalist models to match or surpass specialized CFMs, their substantially greater computational cost and variable AUPRC performance in the fine-tuning setting warrant caution. We provide a reproducible evaluation framework and codebase to support continued benchmarking.

1 June 2026 in JMIR AI
Verified
Journal Article
Open access
BMBingyu Mao
Bingyu Mao
ZXZiqian Xie
Ziqian Xie
LRLaila Rasmy
Laila Rasmy
MNMasayuki Nigo
Masayuki Nigo
DZDegui Zhi
Degui Zhi
Background: Vancomycin is a widely used antibiotic that requires therapeutic drug monitoring (TDM) for optimized individual dosage. A deep learning–based model, pharmacokinetic recurrent neural network–1 compartment model (PKRNN-1CM), has shown the advantage of leveraging time-series electronic health record data for individualized estimation of vancomycin pharmacokinetic (PK) parameters. While 1-compartment PK models are commonly used because of their simplicity and previous trough-based clinical practices for dose adjustment, the pre–deep learning literature suggests the superiority of 2-compartment models. Objective: This study introduces the pharmacokinetic recurrent neural network–2 compartment model (PKRNN-2CM), a novel deep learning–based model designed to improve vancomycin TDM by integrating a 2-compartment PK framework. Methods: PKRNN-2CM combines recurrent neural network–driven PK parameter estimation with a 2-compartment PK model to predict vancomycin concentration trajectories. Training on both simulated data and real-world electronic health record data allows for a comprehensive evaluation of its performance. Results: Experiments based on simulated data highlight PKRNN-2CM’s superiority over the simpler 1-compartment model, PKRNN-1CM, in predicting vancomycin concentration measurements (root mean square error 3.04 vs 4.50). Application to a real dataset from 5483 patients showcases significant improvement over PKRNN-1CM (root mean square error 5.55 vs 5.65; 2-sample 2-tailed unpaired t test; P =.01), with potential further gains expected with nontrough level measurements. Our simulation also indicates that PKRNN-2CM offers a better estimate of the average area under the concentration-time curve to minimum inhibitory concentration ratio, a more clinically relevant measure. Conclusions: PKRNN-2CM is an important improvement in vancomycin TDM, demonstrating enhanced accuracy and performance compared to the PKRNN-1CM model. This deep learning model holds potential for future individualized vancomycin TDM optimization and broader applications in diverse clinical scenarios.

31 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
BMBingyu Mao
Bingyu Mao
ZXZiqian Xie
Ziqian Xie
MNMasayuki Nigo
Masayuki Nigo
LRLaila Rasmy
Laila Rasmy
DZDegui Zhi
Degui Zhi
Objective Vancomycin is a widely used antibiotic that requires therapeutic drug monitoring (TDM) for optimized individual dosage. The deep learning-based model PKRNN-1CM has shown the advantage of leveraging time series electronic health record (EHR) data for individualized estimation of vancomycin pharmacokinetic (PK) parameters. While one-compartment (1CM) PK models are commonly used because of their simplicity and previous trough-based clinical practices for dose adjustment, the pre-deep learning literature suggests the superiority of two-compartment models (2CM). Motivated by this, we introduce a novel deep-learning-based approach, PKRNN-2CM, for vancomycin TDM. Methods PKRNN-2CM combines RNN-driven PK parameter estimation with a 2CM PK model to predict vancomycin concentration trajectories. Training on both simulated data and real-world EHR data allows for a comprehensive evaluation of its performance. Results Experiments based on simulated data highlight PKRNN-2CM’s superiority over the simpler 1CM model PKRNN-1CM (PKRNN-2CM RMSE=1.30, PKRNN-1CM RMSE=2.50). Application to real data showcases significant improvement over PKRNN-1CM (PKRNN-2CM RMSE=5.62, PKRNN-1CM RMSE=5.84, two-sample unpaired t-test p-value=0.01), with potential further gains expected with non-trough level measurements. Conclusion PKRNN-2CM is an important improvement in vancomycin TDM, demonstrating enhanced accuracy and performance compared to the PKRNN-1CM model. This deep learning model holds potential for future individualized vancomycin TDM optimization and broader application in diverse clinical scenarios.

4 June 2026 in JMIR Formative Research
Verified
Journal Article
Open access
APAnil Patwardhan
Anil Patwardhan
NVNishant Verma
Nishant Verma
PBPoulami Barman
Poulami Barman
BMBingyu Mao
Bingyu Mao
NLNan Li
Nan Li
LLLisa Soleymani Lehmann
Lisa Soleymani Lehmann